1-[4-(4-异丙基苯氧基)-苯基]-乙酮 | 887574-95-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-[4-(4-异丙基苯氧基)-苯基]-乙酮
• 英文名称: 1-(4-(4-isopropylphenoxy)phenyl)ethan-1-one
• 英文别名: 1-[4-(4-Isopropyl-phenoxy)-phenyl]-ethanone；1-[4-(4-propan-2-ylphenoxy)phenyl]ethanone
• CAS: 887574-95-0
• 化学式: C₁₇H₁₈O₂
• mdl: MFCD06657004
• 分子量: 254.329
• InChiKey: AIYPFUZUKLFFRO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.235
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-[4-(4-异丙基苯氧基)-苯基]-乙酮 在 乌洛托品 、 copper(ll) bromide 作用下， 以 氯仿 、 乙酸乙酯 为溶剂， 反应 52.0h， 生成
  参考文献：
  名称：

  PTP1B选择性抑制剂不带电荷的儿茶酚衍生物的设计，合成和生物学评估

  摘要：

  蛋白质酪氨酸磷酸酶1B（PTP1B）是有效治疗T2DM和肥胖症的有希望且经过验证的治疗靶标。但是，带电的PTP1B抑制剂由于其低的细胞渗透性和较差的生物利用度而受到限制。基于活性天然产物，通过靶向磷酸二芳基酯结合位点和催化位点，鉴定了两个系列的不带电荷的邻苯二酚衍生物为PTP1B抑制剂。最有效的抑制剂22对PTP1B的IC 50为0.487μM，相对于TCPTP具有很强的选择性（27倍）。还进行了动力学研究，发现22种可作为竞争性PTP1B抑制剂。22例C2C12肌管的治疗显着增加了IRβ，Akt和IRS1的磷酸化水平。其作用谱与胰岛素产生的相似，表明其作为一种新的非胰岛素依赖性候选药物的潜力。

  DOI：

  10.1016/j.ejmech.2017.05.007
• 作为产物：
  描述：

  4-异丙基苯酚 、 4-溴苯乙酮 在 copper(l) iodide 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 生成 1-[4-(4-异丙基苯氧基)-苯基]-乙酮
  参考文献：
  名称：

  PTP1B选择性抑制剂不带电荷的儿茶酚衍生物的设计，合成和生物学评估

  摘要：

  蛋白质酪氨酸磷酸酶1B（PTP1B）是有效治疗T2DM和肥胖症的有希望且经过验证的治疗靶标。但是，带电的PTP1B抑制剂由于其低的细胞渗透性和较差的生物利用度而受到限制。基于活性天然产物，通过靶向磷酸二芳基酯结合位点和催化位点，鉴定了两个系列的不带电荷的邻苯二酚衍生物为PTP1B抑制剂。最有效的抑制剂22对PTP1B的IC 50为0.487μM，相对于TCPTP具有很强的选择性（27倍）。还进行了动力学研究，发现22种可作为竞争性PTP1B抑制剂。22例C2C12肌管的治疗显着增加了IRβ，Akt和IRS1的磷酸化水平。其作用谱与胰岛素产生的相似，表明其作为一种新的非胰岛素依赖性候选药物的潜力。

  DOI：

  10.1016/j.ejmech.2017.05.007

文献信息

• Design, synthesis and biological evaluation of uncharged catechol derivatives as selective inhibitors of PTP1B
  作者：Xiang-Qian Li、Qi Xu、Jiao Luo、Li-Jun Wang、Bo Jiang、Ren-Shuai Zhang、Da-Yong Shi

  DOI：10.1016/j.ejmech.2017.05.007

  日期：2017.8

  obesity. However, the development of charged PTP1B inhibitors was restricted due to their low cell permeability and poor bioavailability. Based on active natural products, two series of uncharged catechol derivatives were identified as PTP1B inhibitors by targeting a secondary aryl phosphate-binding site as well as the catalytic site. The most potent inhibitor 22 showed an IC50 of 0.487 μM against PTP1B and

  蛋白质酪氨酸磷酸酶1B（PTP1B）是有效治疗T2DM和肥胖症的有希望且经过验证的治疗靶标。但是，带电的PTP1B抑制剂由于其低的细胞渗透性和较差的生物利用度而受到限制。基于活性天然产物，通过靶向磷酸二芳基酯结合位点和催化位点，鉴定了两个系列的不带电荷的邻苯二酚衍生物为PTP1B抑制剂。最有效的抑制剂22对PTP1B的IC 50为0.487μM，相对于TCPTP具有很强的选择性（27倍）。还进行了动力学研究，发现22种可作为竞争性PTP1B抑制剂。22例C2C12肌管的治疗显着增加了IRβ，Akt和IRS1的磷酸化水平。其作用谱与胰岛素产生的相似，表明其作为一种新的非胰岛素依赖性候选药物的潜力。
• Toward a treatment of diabesity: In vitro and in vivo evaluation of uncharged bromophenol derivatives as a new series of PTP1B inhibitors
  作者：Xiangqian Li、Qi Xu、Chao Li、Jiao Luo、Xiuxue Li、Lijun Wang、Bo Jiang、Dayong Shi

  DOI：10.1016/j.ejmech.2019.01.057

  日期：2019.3

  Protein tyrosine phosphatase 1B (PTP1B) has been considered as a validated biological target for type 2 diabetes treatment, but past endeavors to develop inhibitors of PTP1B into drugs have been unsuccessful. Two challenging aspects are selective inhibition and cell permeability. A structure-based strategy was employed to develop uncharged bromophenols as a new series of PTP1B inhibitors. The most potent compound 22 (LXQ46) inhibited PTP1B with an IC50 value of 0.190 mu M, and showed remarkable selectivity over other protein tyrosine phosphatases (PTPs, 20-200 folds). In the SPR study, increasing concentrations of compound 22 led to concentration-dependent increases in binding responses, indicating that compound 22 could bind to the surface of PTP1B via noncovalent means. By treating insulin resistant C2C12 myotubes with compound 22, enhanced insulin and leptin signaling pathways were observed. Long-term oral administration of compound 22 reduced the blood glucose level of diabetic BKS db mice. The glucose tolerance tests (OGTT) and insulin tolerance tests (ITT) in BKS db mice showed that oral administration of compound 22 could increase insulin sensitivity. In addition, long-term oral administration of compound 22 could protect mice from obesity, which was not the result of toxicity. Our pharmacokinetics results from the rat-based assays showed that orally administered compound 22 was absorbed rapidly from the gastrointestinal tract, extensively distributed to the tissues, and rapidly eliminated from the body. All these results indicate that compound 22 could serve as a qualified agent to treat type II diabetes. (C) 2019 Elsevier Masson SAS. All rights reserved.
• Nickel-Catalyzed Etherification of Phenols and Aryl Halides through Visible-Light-Induced Energy Transfer
  作者：Da-Liang Zhu、Shan Jiang、Qi Wu、Hao Wang、Hai-Yan Li、Hong-Xi Li

  DOI：10.1021/acs.orglett.1c03066

  日期：2021.11.5

  arylhalides, the ability of such a Ni-catalyzed transformation employing phenols to diaryl ethers is unsuccessful due to phenolates with much lower reduction potentials, which suppress the oxidation of nickel(II) intermediates into requisite Ni(III) species. We herein report visible-light-initiated, nickel-catalyzed O-arylation of phenols with arylhalides using t-BuNH(i-Pr) as the base and thioxanthen-9-one

  尽管在链烷醇和芳基卤化物的镍催化醚化方面取得了一些进展，但由于苯酚盐的还原电位低得多，从而抑制了镍 (II) 中间体氧化成必需的化合物，因此这种使用苯酚的镍催化转化为二芳基醚的能力并不成功Ni(III) 物种。我们在此报告了在可见光下使用t- BuNH( i- Pr) 作为碱和thioxanthen -9-one 作为光敏剂的可见光引发的镍催化苯酚与芳基卤化物的O-芳基化。这种光电耦合表现出广泛的基板范围。